"Citron's reports are a lot more fun to read than just about anything published by a mainstream Wall Street stock analyst."
-- Bloomberg News

July 05, 2015
HomeReportsArchivesContact Us / SuggestionsLegal DisclaimerWho is Citron

AXDX Big Lie Exposed by SEC — $1.00 Target within 18 Months

Posted in Citron Reports by Stocklemon on the March 9th, 2015

It is well known that Accelerate Diagnostics (NASDAQ:AXDX) is a controversial stock.  Here are the main reasons:

*   11 years of unfulfilled promises about the same product

*   No viable commercial product on the immediate horizon

*   Scant R&D

*   Technology rejected by two major pharma companies, who each had exclusive rights to AXDX's platform for months — and then walked away

*   Not a single independent scientific publication on its technology — despite over 30 papers authored by employees, and individuals compensated by the company

*   A competitive landscape increasingly crowded with high-credibility and well funded competitors, each aggressively bringing new technologies to market — many already FDA approved and/or Europe CE approval

Citron won't rehash previously published stories about his company's suspect past, but rather focus on the heart of what is new, unreported and publicly sourced.  We'll step you through the extraordinary sequence in which the SEC at its finest, forces the company to fess up and abandon its 10+ year misleading overreach of a story about rapid diagnostics using direct from patient blood samples.

This company's claim to innnovative medical diagnostic technology has been exposed by its own filings.  It is careening toward irrelevance without a viable product. 


For the Story You Won't Read Anywhere Else, Click Here

(As always, Citron recommends you download the PDF, then right-click to follow the links)

GoPro to $30 Within 12 Months — The Comps Wall Street Isn’t Talking About

Posted in Citron Reports by Stocklemon on the November 4th, 2014

Citron Debunks the Hardware plus Media Story with Spot-On Comps

Over the past month Citron has read over 100 articles and analyst comments about GoPro (NASDAQ:GPRO), both positive and negative. To date, not a single commentator or analyst has laid out the truth regarding this company's promotional "we're a media company" story.  

Citron decisively documents the irreconcilable gap between the most optimistic conceivable valuation that this company can ever command, and the current stock price.

For the rest of the story you won't read anywhere else, click here:

(As always, Citron recommends that you right-click to download the PDF, then follow the links to sources)

« Previous PageNext Page »

3 queries in 0.207 seconds